Therapeutic Expertise

Rheumatology

Characteristics of Rheumatology Clinical Trials

Clinical studies in the field of rheumatology have a long follow-up cycle, and the patients’ medications are mostly complex and varied. Presently, competition in clinical development is gradually increasing and most of the current clinical trials are with biologicals which have a long half-life and long follow-up period.

In these studies, many patients drop out due to intolerable joint pain causing them to change the therapeutic regimen. Additionally, the inclusion and exclusion criteria are strict on requirements regarding the subjects’ prior medication and medical history, therefore the screening failure rate is high.

200+

Rheumatology Clinical Trials

80+

Dermatology
Trials

60+

Nephrology
Trials

50+

Rheumatology Trials

46,000+

Patients Enrolled

End-to-End Clinical Development Solutions in Immunology

End-to-end immunology clinical development solutions, spanning from early-phase to post-approval. Our integrated services cover the entire drug development lifecycle, including Regulatory Affairs, Medical Affairs, Clinical Development Strategy, Clinical Operations, and Biometrics.

Extensive network of Key Opinion Leaders (KOLs) in immunology—particularly indermatology, rheumatology and nephrology—with long-standing partnerships across top-tier clinical trial sites.

A specialized team dedicated to immunology clinical development, with extensive operational expertise and a 100% pass rate in NMPA on-site inspections.

Dermatology: Adult/Adolescent AD | Psoriasis | Alopecia Areata | Alopecia | Urticaria | Acne
Rheumatology: Gout | SLE | RA | AS
Nephrology: IgAN | DKD | Membranous Nephropathy | Renal Anemia | Nephrotic Syndrome

Let's Connect for a Conversation